Program
pediarix
Also written as “Pediarix”, “Infanrix™ penta” and “Infanrix penta”.
Its studies are mostly in Haemophilus Infections · Rotavirus Infections · Hepatitis B, led by 2 companies.
Drug pagePediarix: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKlineits history only | 80 open or running | phase 3since Feb 9, 2006 | Aug 10, 2005 | none ahead |
| Pfizer | 11 open or running | phase 3since Aug 14, 2025 | Aug 14, 2025 | Nov 6, 2028phase 3 · NCT07160244 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Pfizer only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 14, 2025First study: phase 3 study in HealthyFirst studyNCT07160244 · 6,000 planned · United States, Argentina, Brazil and more
Ahead
- Nov 6, 2028Primary completion: phase 3 study in HealthyNCT07160244
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“A vaccine consisting of detoxified tetanus toxoid, detoxified diphtheria toxoid, acellular pertussis antigens, inactivated poliovirus (IPV) types 1,2 and 3 and hepatitis B (HBV) surface antigen, with active immunizing activities against diphtheria, tetanus, pertussis, hepatitis B, and poliomyelitis”NCIt, by rule
Studies
The one study Pfizer leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07160244Healthy · United States, Argentina, Brazil and more | 3 | Recruiting | Nov 6, 2028 | 6,000 |
How it is read
Names in the registry
- “Pediarix”, 3 entries
- “Infanrix™ penta”, 2 entries
- “Infanrix penta”, 1 entry
- “Infanrix penta ®”, 1 entry
- “Pediarix™”, 1 entry
Conditions, from the studies’ own filings
- Haemophilus Infections, 6 studies
- Rotavirus Infections, 1 study
- Hepatitis B, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.